Is asymmetric dimethylarginine associated with being born small and large for gestational age?

Area of Science:

• Pediatric Endocrinology
• Cardiovascular Research
• Metabolic Health

Background:

• Low and high birth weight (small for gestational age [SGA], large for gestational age [LGA]) are associated with cardiovascular and metabolic issues.
• The progression of these issues and reliable biomarkers in SGA/LGA children remain unclear.
• Asymmetric dimethylarginine (ADMA), a nitric oxide (NO) antagonist, is a recognized cardiovascular risk marker in adults.

Purpose of the Study:

• To investigate circulating ADMA and NO levels in SGA and LGA children compared to appropriate for gestational age (AGA) peers.
• To explore the relationship between ADMA levels and cardiometabolic risk factors in these pediatric populations.
• To assess the potential role of ADMA as an early biomarker for cardiometabolic alterations in SGA and LGA children.

Main Methods:

• Cross-sectional study comparing ADMA and NO levels in SGA, LGA, and AGA children.
• Measurement of serum ADMA and NO concentrations.
• Assessment of insulin resistance and other cardiometabolic parameters.

Main Results:

• ADMA levels were significantly elevated in both SGA and LGA children compared to AGA children.
• Both SGA/LGA status and insulin resistance were independently associated with higher ADMA levels.
• These findings suggest a potential link between birth weight extremes, ADMA, and early cardiometabolic changes.

Conclusions:

• Elevated ADMA in SGA and LGA children may indicate an increased predisposition to cardiometabolic disturbances.
• ADMA could serve as a potential early biomarker for cardiovascular risk in these pediatric groups.
• Further research is warranted to elucidate the precise role of ADMA in the development of cardiometabolic alterations from prepubertal age.